CI - Kala's dry eye drug Eysuvis gets coverage by UnitedHealthcare Commercial Cigna Medicare

Kala Pharmaceuticals (NASDAQ:KALA) said that UnitedHealthcare (NYSE:UNH) added dry eye disease therapy Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022, expanding commercial coverage to 118M people. In addition Kala said that Cigna (NYSE:CI) Medicare has added Eysuvis as a preferred brand effective February 2022, adding an additional 1.9M Medicare lives. Eysuvis now has Medicare preferred coverage for select plans with Express Scripts, Prime Therapeutics and Cigna. Total Eysuvis Medicare coverage is now ~7.1M people. KALA +3.46% pre-market to $0.63

For further details see:

Kala's dry eye drug Eysuvis gets coverage by UnitedHealthcare Commercial, Cigna Medicare